Effects of Danicamtiv, a Novel Cardiac Myosin Activator, in Heart Failure with Reduced Ejection Fraction: Experimental Data and Clinical Results from a Phase 2a Trial

A. Voors, Adriaan; Tamby, Jean‐François; G.F. Cleland, John; J. Koren, Michael; B. Forgosh, Leslie; Gupta, Dinesh; H. Lund, Lars; Camacho, Albert; Karra, Ravi; P. Swart, Henk; Pellicori, Pierpaolo; Wagner, Frank; E. Hershberger, Ray; Prasad, Narayana; L. Anderson, Robert; Anto, Anu; M. Bell, Kaylyn; M. Edelberg, Jay; Fang, Liang; Henze, Marcus; M. Kelly, Cynthia; Kurio, Gregory; Li, Wanying; Wells, Kate; Yang, Chun; L. Teichman, Sam; del Río, Carlos; D. Solomon, Scott

doi:10.1002/ejhf.1933

Public

Effects of Danicamtiv, a Novel Cardiac Myosin Activator, in Heart Failure with Reduced Ejection Fraction: Experimental Data and Clinical Results from a Phase 2a Trial

Published in European Journal of Heart Failure • Jun 19, 2020

Authors:

Adriaan A. Voors

Jean‐François Tamby

John G.F. Cleland

Abstract

Abstract Aims Both left ventricular (LV) and left atrial (LA) dysfunction and remodelling contribute to adverse outcomes in heart failure with reduced ejection fraction (HFrEF). Danicamtiv is a novel, cardiac myosin activator that enhances cardiomyocyte contraction. Methods and results We studied th...

Subject

Ejection fraction

Medicine

Heart failure

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!